Correspondence:
- 1.
- NIH Consensus Conference. Impotence, NIH Consensus DevelopmentPanel on Impotence. JAMA 1993; 270: 83-90.
- 2.
- Pinnock CB, Stapleton AM, Marshall VR. Erectile dysfunction in thecommunity: a prevalence study. Med J Aust 1999; 171: 353-357.
- 3.
- Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the UnitedStates: prevalence and predictors. JAMA 1999; 281: 537-544.
- 4.
- Linet OI, Ogrinc FG. Efficacy and safety of intra-cavernosalalprostadil in men with erectile dysfunction. The Alprostadil StudyGroup. N Engl J Med. 1996; 334: 873-877.
- 5.
- National Health and Medical Research Council. A guide to thedevelopment, implementation and evaluation of clinical practiceguidelines. Canberra: NHMRC, AusInfo, 1999.
- 6.
- Poch G, Kukovetz WR. Papaverine-induced inhibition ofphosphodiesterase activity in various mammalian tissues. LifeSci 1971; 10: 133-144.
- 7.
- Hakenberg O, Wetterauer U, Koppermann U, Liffimann R. Systemicpharmacokinetics of papaverine and phentolamine: Comparison ofintravenous and intracorporal application. Int J ImpotenceRes 1990; 2 (Suppl 2): 247-248.
- 8.
- Porst H. The rationale for prostaglandin E1 in erectile failure: asurvey of world-wide experience. J Urol 1996; 155: 802-815.
- 9.
- De Rose AF, Oppezzi GF, Scotto S. [Local complications ofpapaverine-induced erection: follow-up at 7 years] [Article inItalian]. Arch Ital Urol Androl 1993; 65: 289-293.
- 10.
- Brown LS, Christopher AH, Koehler M, et al. Hepatotoxicityrelated to intracorporal pharmacotherapy with papaverine.Urology 1998; 52: 844-847.
- 11.
- Paoletti R. Biochemistry and pharmacology of prostaglandin E1:introductory remarks. In: Sinzinger H, Rogatti W, editors.Prostaglandin E1 in atherosclerosis. New York: Springer-Verlag,1986: 3-7.
- 12.
- Chen RN, Lakin MM, Montague DK, Ausmundson S. Penile scarring withintracorporal injection therapy using prostaglandin E1: a riskfactor analysis. J Urol 1996; 155: 138-140.
- 13.
- Chew KK, Stuckey BG, Earle CM, et al. Penile fibrosis inintracavernosal prostaglandin E1 injection therapy for erectiledysfunction. Int J Impotence Res 1997; 9: 225-229;discussion, 229-230.
- 14.
- Moreland RB, Traish A, McMillin MA, et al. PGE1 suppresses theinduction of collagen synthesis by transforming growth factor-beta1 in human corpus cavernosum smooth muscle. J Urol 1995; 153:826-834.
- 15.
- Padma-Nathan H. The efficacy and synergy of polypharmacotherapyin primary and salvage therapy of vasculogenic erectile failure.Int J Impotence Res 1990; 2: 257-258.
- 16.
- McMahon CG. Comparison of the response to the intracavernosalinjection of a combination of papaverine and phentolamine,prostaglandin E1 alone and a combination of all three in themanagement of impotence. Int J Impotence Res 1991; 3:133-142.
- 17.
- Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of menwith erectile dysfunction with transurethral alprostadil.Medicated Urethral System for Erection (MUSE) Study Group. N EnglJ Med 1997; 336: 1-7.
- 18.
- Fulgham PF, Cochran JS, Denman JL, et al. Disappointing initialresults with transurethral alprostadil for erectile dysfunction ina urology practice setting. J Urol 1998; 160: 2041-2046.
- 19.
- Porst H. Transurethral alprostadil with MUSE (medicatedurethral system for erection) vs intracorporal alprostadil -- acomparative study in 103 patients with erectile dysfunction. IntJ Impotence Res 1997; 9: 187-192.
- 20.
- Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in thetreatment of erectile dysfunction. Sildenafil Study Group. NEngl J Med 1998; 338: 1397-1404.
- 21.
- Dinsmore WW, Hodges M, Hargreaves C, et al. Sildenafil citrate(Viagra) in erectile dysfunction: near normalization in men withbroad-spectrum erectile dysfunction compared with age-matchedhealthy control subjects. Urology 1999; 53: 800-805.
- 22.
- Jarow JP, Burnett AL, Geringer AM. Clinical efficacy ofsildenafil citrate based on etiology and response to priortreatment. J Urol 1999; 162: 722-725.
- 23.
- McMahon CG, Samali R, Johnston HM. Treatment of IntracorporalInjection Non-Responders with Sildenafil Alone or in Combinationwith Polyagent Intracorporal Injections. J Urol 1999; 162:1992-1997.
- 24.
- Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expertconsensus document. Use of sildenafil (Viagra) in patients withcardiovascular disease. American College of Cardiology/AmericanHeart Association. J Am Coll Cardiol 1999; 33: 273-282.
- 25.
- Always use alprostadil monotherapy as first-line ICI treatment.
- 26.
- Use lowest possible effective dose.
- 27.
- Inform patient of the risk of prolonged erection and the procedure to be followed if the penis is still rigid, as follows:
Online responses are no longer available. Please refer to our instructions for authors page for more information.